TEST MENU
|
|
- Pauline Elliott
- 5 years ago
- Views:
Transcription
1 CISH EBV (EBER1 RNA) EBVISH CISH Kappa by ISH or CISH Lambda by ISH or Cytogenetics Chromosomal Analysis Cytogenetics 88237, 88264, 88280, (may include or additional units of 88280; used in lieu of for solid tumor) 11q22.3 (ATM) CLL/SLL Panel test q23 MLL (Breakapart) MLL (11q23) t(11q23) MLL Acute Lymphocytic Leukemia Panel test q14.3_D13S319 CLL/SLL Panel test Myeloma Panel test Myeloproliferative Disorder (MPD) Panel test p13.1_P53 CLL/SLL Panel test; Myeloma Panel test p36/19q13 â Oligodendroglioma Oligodendroglioma Panel test (1p36/1q25 and 19q13/19p13) 88374x2 1q21+1p21 Myeloma Panel Test q12 MDS Panel test; Myeloproliferative Disorder (MPD) Panel test or q31 / del 7q 7q31/CEP7 MDS Panel test Acute Myelogenous Leukemia Panel test ALK (2P23) translocations EML4-ALK ALL (Acute Lymphocytic Leukemia) Panel This is a send out panel. Probes vary by vendor, and Client may be billed for the testing. Contact PhenoPath Client Services for details. Call to confirm AML (Acute Myelogenous Leukemia) Panel t(8;21) RUNX1/RUNX1T1 t(15;17) PML/RARA CBFB 88374x6, inv16 breakapart 7/del 7q 11q23 CEP8 (trisomy) EGR1 (5q31/5p15.5) * Panel makeup subject to change APL (Acute Promyelocytic Leukemia) Panel t(15;17) PML/RARA RARA (17q21) brreakapart 88374x2 (reference only; * Panel makeup subject to change BCL6 (3q27) n Hodgkin Lymphoma (Agressive B- BCL6 translocations NHL) Panel test n Hodgkin Lymphoma (Indolent B- NHL) Panel test CBFB inv(16) Breakapart CBFB inv16 Acute Myelogenous Leukemia Panel test CEP-X/Y CEP12 CEP12 (12p11.1) CLL/SLL Panel test or CEP17-Hydatidiform Mole Hydatidiform Mole Panel test or CEP8 (Trisomy) Trisomy 8 MDS Panel test Acute Myelogenous Leukemia Panel test Myeloproliferative Disorder (MPD) Panel test or CLL/SLL Panel 11q22.3_ATM 13q14_D13S319 13q34_LAMP 17p13.1_P53 CEP12 (trisoomy) IGH breakapart t(11;14) CCND1/IGH * Panel makeup subject to change 88374x5, CML Panel t(9;22) BCR/ABL (reference only; Copy Control 9 (CC9) CEP9 (9p11-q11.1) Myeloma Panel test Myeloproliferative Disorder (MPD) Panel test or EGFR/CEP EGR1 (5q31/5p15.5) 5q31/5p15.5 MDS Panel test AML Panel test EWSR1 Breakapart FUS Breakapart HER2/CEP17 (PathVysion) ; 88360; 88367; Hydatidiform Mole Evaluation (Molar p57 and Ki-67 (MIB-1) by CEP17 by * Panel (reference only; Pregnancy) makeup subject to change Hyperdiploidy probes CC3, CEP5, CEP7, CEP11, CC15 IGH Breakapart IGH (14q32) CLL/SLL Panel test MYC Panel test n Hodgkin Lymphoma (Agressive B-NHL) Panel test n Hodgkin Lymphoma (Indolent B-NHL) Panel test MALT Panel MALT1 (18q21) (reference only; MALT1 Breakapart n Hodgkin Lymphoma (Indolent B-NHL) Panel test MALT Panel test MALT1 Breakapart (18q21) positive, reflex t(11;18) MALT1/API2 t(14;18) IGH/MALT1 * Panel 88374x2 (reference only; panel makeup subject to change MDM-2/SE12 MDM MDS (Myelodysplastic Syndrome) Panel 88374x2, 88367; EGR1 (5q31/5p15.5) 7/del 7q CEP8 Deletion 20q * Panel makeup subject to change 1 of 7
2 MET (7q31.2) / CC7 CMET, c-met, hepatocyte growth factor receptor, HGFR MYC Breakapart c-myc n Hodgkin Lymphoma (Agressive B-NHL) Panel test MYC Panel test ALL Panel test: MYC (8q24) rearrangements Myeloma Panel 1q21+1p21 13q14.3_D13S319 13q34_LAMP 88374x6, 88367; 88373x5 17p13.1_P53 t(11;14) CCND1/IGH t(14;16) IGH/MAF (reference only; panel run t(4;14) FGFR3/IGH Copy Control 3 (CC3) CEP5 as algorithm; CPTs may CEP7 Copy Control 9 (CC9) CEP11 Copy Control 15 (CC15) * Panel makeup subject to change Myeloproliferative Neoplasm (MPN) Panel n Hodgkin Lymphoma (Aggressive B- NHL) Panel n Hodgkin Lymphoma (Indolent B-NHL) Panel - Paraffin n Hodgkin Lymphoma (Indolent B-NHL) Panel - Wet Alternate name: MPD Panel 13q14.3_D13S319 Deletion 20q CEP8 (trisomy) Copy Control 9 (CC9) (hyperdiploidy) * Panel makeup subject to change MYC (8q24) breakapart IGH breakapart t(14;18) IGH/BCL2 BCL6 breakapart * Panel makeup subject to change IgH breakapart t(14;18) IGH/BCL2 BCL6 breakapart t(11;14) CCND1/IGH MALT1 breakapart * Panel makeup subject to change IgH breakapart t(14;18) IGH/BCL2 BCL6 breakapart t(11;14) CCND1/IGH * Panel makeup subject to change 88374, 88367; 88373x x4 (reference only; 88374x5 (reference only; 88374x4 (reference only; P16 (CDKN2A)/CC9 CDKN2A/CC RARA Breakapart RARA (17q12) RET Breakapart Chromosome 10q ROS-1 Breakapart SS18-SYT-synovial sarcoma-x18 SS18 (SYT-18q11.2) t(11;14)(q13;q32) (IGH/CCND1) Myeloma Panel test t(11;14) CCND1/IGH CLL/SLL Panel test n Hodgkin Lymphoma (Indolent B-NHL) Panel test t(11;18) MALT1/API2 (& MALT1/BIRC3) t(11;18)(q21;q21) (API2/MALT1) t(11;18)(q21;q21) (BIRC3/MALT1) MALT1 (18q21) positive Reflex Panel test t(14;16) IGH/MAF t(14;16)(q32;q23) (IGH/MAF) t(14;18) IGH/BCL2 t(14;18)(q32;q21) (IGH/BCL2) n Hodgkin Lymphoma (Indolent B-NHL) Panel test n Hodgkin Lymphoma (Aggressive B-NHL) Panel test t(14;18) IGH/MALT t(14;18)(q32;q21) MALT1 MALT1 (18q21) positive Reflex Panel test t(15;17) PML/RARA t(15;17)(q22;q21.1) (PML/RARA) Acute Promyelocytic Leukemia Panel test Acute Myelogenous Leukemia Panel test t(4;14) FGFR3/IGH t(4;14)(p16;q32) (IGH/FGFR3) Myeloma Panel test t(8;14)(igh/myc) NHL (Aggressive B-NHL) Panel test t(8;21) (RUNX1/RUNX1T1) t(8;21) Acute Myelogenous Leukemia Panel test t(9;22) BCR/ABL t(9;22)(q34;q11.2) (BCR/ABL) Acute Lymphocytic Leukemia Panel test CML Panel test TFE3(Xp11) TOP2A/CEP17 TOP2A B-ALL add-on tube CD11b, CD19, CD22, CD33, CD34, CD45, CD56, 88185x10 (reference only; CD79b, HLA-DR, TdT B-ALL minimal residual disease panel x 1, x 8, CD5, CD10, CD19, CD20, CD34, CD38, CD45, x 1 (reference only; kappa, lambda CD5-positive B cell therapy add-on tube CD5, CD19, CD22, CD45, CD52, CD79b, CD49d 88185x7 (reference only; CLL / SLL / mantle cell lymphoma (MCL) addon tube Cytoplasmic lineage add-on tubes Follicular lymphoma (FL)/Burkitt lymphoma (BL) add-on tubes Full bone marrow screening panel Hairy cell leukemia/marginal zone lymphoma add-on tube CD5, CD19, CD22, CD23, CD43, CD45, CD200, FMC7 CD3, CD19, CD34, CD38, CD45, CD79a, CD117, myeloperoxidase bcl-2, CD5, CD10, CD11c, CD19, CD20, CD38, CD45 CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11b, CD13, CD14, CD15, CD16, CD19, CD20, CD33, CD34, CD36, CD38, CD45, CD56, CD64, CD71, CD117, CD123, HLA-DR, kappa, lambda CD5, CD11c, CD19, CD22, CD25, CD38, CD45, CD103 Large T cell therapy add-on tube CD3, CD25, CD30, CD45, CD52, HLA-DR Myeloid 4 add-on tube Myeloid 5 add-on tube CD9, CD19, CD34, CD38, CD45, CD90, CD117, CD133, HLA-DR CD11c, CD34, CD41, CD45, CD61, CD117, CD235a (glycophorin A) 88185x10 (reference only; 88185x8 (reference only; 88185x8 (reference only; x 1, x 26, x 1 (reference only; 88185x8 (reference only; 88185x6 (reference only; 88185x9 (reference only; 88185x7 (reference only; 2 of 7
3 88184 x 1, x 9, Paroxysmal nocturnal hemoglobinuria (PNH) CD10, CD14, CD16, CD24, CD33, CD45, CD59, x 1 (reference only; panel CD235a/glycophorin A, FLAER, HLA-DR Rule out lymphoma panel Rule out mastocytosis panel Rule out plasma cell dyscrasia panel T cell receptor add-on tube T cell therapy add-on tube T-ALL add-on tube CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD19, CD20, CD34, CD38, CD45, CD56, kappa, lambda CD2, CD4, CD25, CD33, CD34, CD38, CD45, CD117, HLA-DR CD5, CD19, CD20, CD45, CD38, CD56, kappa, lambda, surface antibodies x 1, x 14, x 1 (reference only; x 1, x 8, x 1 (reference only; x 1, x # of antibodies, x 1 CD3, CD4, CD5, CD8, CD45, CD56, TCR-alpha-beta, 88185x8 (reference only; TCR-gamma-delta CD3, CD4, CD5, CD8, CD279, CD25, CD45, CD52, 88185x8 (reference only; CD16 CD1a, CD3, CD33, CD34, CD45, CD99, HLA-DR, 88185x8 (reference only; TdT x 1, x 8, x 1 (reference only; T-ALL minimal residual disease panel CD1a, CD2, CD3, CD4, CD5, CD8, CD34, CD45, CD56 ACTH or Adenovirus or ALK protein (p80) or Alpha-1-antitrypsin or Alpha-fetoprotein AFP or AMACR (p504s) Alpha-methylacyl-CoA racemase; p504s or Amyloid A AA or Amyloid Beta or Amyloid P or Amyloid A Amyloid P Component Kappa Light Chains Amyloid Type Analysis Lambda Light Chains Transthyretin Congo Red * 88342; 88341x4; Panel makeup subject to change Androgen Receptor or Arginase-1 Arginase or ATRX Alpha Thalassemia/Mental Retardation Syndrome X- Linked or BAP1 BRCA-associated protein or bcl-10 BCL or bcl-2 (Clone 124) BCL2 clone or bcl-2 (Clone C2) BCL2 (Clone C2) or bcl-6 BCL or Ber-Ep4 (epithelial glycoprotein) BerEp4; epithelial glycoprotein or Beta-catenin Catenin-beta or Bg8 (blood group 8) Lewis Y Antigen or Blood Group A Bld Grp A or Blood Group B BLDGPB Blood Group Antigen B or Bob-1 Bob or Brachyury or Breast Multiplex (CK5/14 + P63 + CK7/18), BRG1 SMARCA or c-kit (CD117) CD117; Stem Cell Receptor; ckit or c-myc cmyc Calcitonin or Caldesmon Clone N5(22) or Calponin or Calretinin or Carbonic Anhydrase IX (CA-IX) CA-IX; CAIX or Cathepsin K or CD10 (CALLA) CALLA or CD103 & PAX and CD123 Alternative test to TRAP or CD or CD or CD or CD or CD or CD1a or CD or CD or CD or CD or of 7
4 CD or CD or CD25 (IL-2Rα) Alternative test to TRAP or CD or CD30 (K-1 antigen) or CD31 PECAM or CD or CD or CD or CD or CD or CD42b Platelet glycoprotein Ib or CD or CD or CD or CD56 (NCAM) NCAM or CD or CD or CD68 (KP-1) KP or CD or CD or CD79a or CD or CD or CDH17 Cadherin 17 LI-Cadherin Liver-Intestine Cadherin human peptide transporter 1 HPT or CDX2 Cdx2-D or CEA [monoclonal II-7] CD66e or CEA [polyclonal, to CEA family (CD66)] CEA polyclonal or Chromogranin A (PHE5) PHE or Clusterin or CXCL or Cyclin D1 Alternative test to TRAP or Cytokeratin 17 Cytokeratin 19 Cytokeratin 20 Cytokeratin 5 Cytokeratin 7 Cytokeratin 8, low molecular weight (35βH11) Cytokeratins (AE1/AE3) Cytokeratins (OSCAR) Cytokeratins, high molecular weight (34βE12) 34BE12 Cytomegalovirus Cocktail CMV cocktail or Desmin or DOG1 DOG or E-cadherin or EBV-LMP or EGFR EMA (Epithelial Membrane Antigen) Epithelial Membrane Antigen or ERG or Estrogen Receptor (clone SP1) or or Fascin or FOXP or FOXP or FSH (Follicle Stimulating Hormone) Follicle Stimulating Hormone or Galectin-3 GAL or Gastrin or GATA-3 GATA3, Clone L or GCDFP-15 (Brst2) Brst or GCET1 GCET-1 Germinal Center B-Cell-Expressed Transcript or GFAP (glial-fibrillary acidic protein) GFP8; glial-fibrillary acidic protein or Glucagon or Glycophorin A or Glypican-3 (GPC3) GPC or Granzyme B or Growth Hormone (GH) GH or H3K27me3 anti-tri-methyl-histone-h3 (Lys27) or Hairy Cell Leukemia (DBA.44) DBA or HBME-1 HBME or HCG (ßHCG) ßHCG or Helicobacter Pylori or of 7
5 Hemoglobin Hmgb or Hepatitis B core antigen Hep B Core or Hepatitis B surface antigen Hep B Surface or HepPar1 Antigen Hepatocyte; CSP1; Carbamoyl phosphate synthetase or HER2 4B5 4B HGAL GCET2, GCAT2, GCSAM or HHV8 (Herpes virus 8, human) Human Herpes Virus 8 KSHV HHV or HLA-DR (MHC class II) Class II histocompatibility antigen; HLADR or HMB-45 (gp100) gp100; Melanoma Specific Antigen; HMB or HSVI & HSVII (Herpes Simplex 1 and 2) Herpes Simplex 1 (HSV1); Herpes Simplex 2 (HSV2) or Human Placental Lactogen (HPL) HPL; Placental Lactogen or IDH1, human Human IDH1 R132H Point Mutation; IDH-1; Isocitrate or dehydrogenase 1 IgA or IgD Immunoglobulin D heavy chain or IgG or IgG4 & Total IgG and and/or x number of additional antibodies performed IgM or IMP3 IMP or Inhibin-Alpha or INI-1 (SMARCB1) SMARCB1; BAF47; INI or INPP4B inositol polyphosphate 4-phosatase type II Insulin or Kappa Light Chains or Keratin 17 Cytokeratin 17 CK or Keratin 19 Cytokeratin 19; CK or Keratin 20 Cytokeratin 20; CK or Keratin 5 Cytokeratin 5; CK5-XM or Keratin 7 Cytokeratin 7; CK or Keratin 8, low molecular weight (35ßH11) Cytokeratin 8; low molecular weight (35ßH11); CK8; 35ßH11; 35BH or Keratins (AE1/AE3) Cytokeratins (AE1/AE3); AE1AE or Keratins (OSCAR) Cytokeratins (OSCAR) or Keratins, high molecular weight (34ßE12) Cytokeratins, high molecular weight (34ßE12); 34BE or Ki-67 Antigen (Clone SP6) Ki67; SP Ki-67 Antigen (MIB-1) Ki67; MIB Lambda Light Chains Lambda Light Chains or Langerin (CD207) CD or LEF1 LEF-1; Lymphoid enhancer-binding factor or LMO or Lutinizing Hormone (LH) or Lysozyme Muraminidase or Macrophage (HAM56) HAM or Mammaglobin A or MART-1 Antigen (Melan A) Melan A; MART or Merkel Cell Polyomavirus (MCPyV) MCPyV; MCPV or Mesothelin or Mitochondria or MLH or MMR (correlates with MSI), including: MLH1; MSH2; MSH6; PMS ; 88341x3 MNDA Myeloid cell Nuclear Differentiation Antigen or MOC-31 MOC31; Epithelial glycoprotein or MSH or MSH or MUM1 Interferon regulatory factor or Muscle actins (HHF35) Actin, muscle specific HHF or Myeloperoxidase or MyoD or Myogenin or Myoglobin Mouse Monoclonal, clone MG or NapsinA Naspin A or Nestin or Neu-N NeuN; A or Neurofilaments (2F11) 2F or NKX2.2 NKX or of 7
6 NKX3.1 NKX or NUT or OCT-2 OCT2.1; Octamer transcription factor or Oct3/4 Oct or p16-ink4a p16; E6H or p40 p63 isoform Î Np or p or p57-kip2 p or p or p75-ntr NGFR or Pancreatic Polypeptide (PP) PP or PAP (Prostatic Acid Phosphatase) Prostatic Acid Phosphatase or Parvovirus B or PAX-5 PAX or PAX-6 PAX or PAX-8 PAX or PD-1 (CD279) PD1; Programmed cell death protein 1; CD or PD-L1 (clone 22C3) pharmdx 22C3 PDL PD-L1 (clone 28-8) pharmdx 28-8 PDL PD-L1 (clone EIL3N) PDL1 Programmed Death-Ligand 1, CD PD-L1 (clone SP142) SP142 PDL PLAP (Placental Alkaline Phosphatase) or PMS or Pneumocystis or PNL2 Melanoma Associated Antigen or Podoplanin (D2-40) D or Polyomavirus (BK, JV & SV40 viruses) BK virus; JC virus (Jamestown Canyon); SV40 virus; SV or Progesterone Receptor (clone PgR 636) PR636-D or or Prolactin or Prostate Multiplex (CK5/14 + P63 + P504S), Multiplex PSA (Prostate Specific Antigen) Prostate Specific Antigen or PTEN Phosphatase and tensin homolog or PTH (Parathyroid Hormone) Parathormone; parathyroid hormone or PU.1 ROS1 ROS, MCF3, c-ros or S-100 S or SALL4 SALL or Serotonin or SF-1 SF or SMMHC (smooth muscle myosin heavy chain) Smooth muscle myosin heavy chain or Smooth muscle actin (clone 1A4) 1A or Smoothelin or Somatostatin or SOX10 SRY-related HMG-Box gene or SOX11 MRQ-58, Sox-11, SOX or SSt2A SSt2A; Somatostatin receptor type 2A SSTR or STAT 6 STAT6 Signal Transducer and Activator of Transcription or Synaptophysin or TCL1 TCL1A; p14tcl1; TCL or TCR-ßF1 TCR beta F1; TCRßF1; TCRBF or TdT Terminal deoxynucleotidyltransferase or Thrombomodulin CD or Thymidylate Synthase (TS) TS Thyroglobulin or Thyroid Stimulating Hormone (TSH) TSH beta, TSH-B or TIA-1 TIA or Toxoplasma Gondii or Transthyretin (Pre Albumin) or Tryptase or TTF-1 (thyroid transcription factor 1) TTF1; Thyroid transcription factor or Type IV Collagen Collagen Type IV or Tyrosinase or Uroplakin or Varicella Zoster (VZV) VZV or Villin or Vimentin or VIP (vasoactive intestinal polypeptide) Vasoactive intestinal polypeptide or vwf (Factor VIII related antigen) von Willebrand Factor or WT-1 WT1; Wilms tumor gene product or of 7
7 ZAP-70 ZAP or ImmunofluoresceComplement C or ImmunofluoresceIgA or ImmunofluoresceIgG or ImmunofluoresceIgM or ImmunofluoresceSerum IF or BCR-ABL1, Major BCR-ABL p210, BCR-ABL Mbcr (reference only; BCR-ABL1, Minor BCR-ABL p190, BCR-ABL mbcr (reference only; 81210; may apply BRAF V600 BRAF V600 (in melanoma) (FDA-approved) V600E (melanoma) 81210; may apply Calreticulin Exon 9 CALR EGFR_Roche cobas EGFR Mutation Test (IVD) cobas EGFR IVD 81235; may apply EGFR_Roche cobas EGFR Plasma Mutation Test (IVD) cobas EGFR PLASMA Extended KRAS/NRAS Panel (KRAS exons 81311, (88381 may KRAS exons 3, 4 NRAS exons 2, 3, & 4 3 & 4, NRAS exons 2,3 & 4) apply) Ig-Kappa gene rearrangement B cell (Kappa) clonality 81264; may apply; IgH (B cell) gene rearrangement B cell (IgH) clonality 81261; may apply; JAK2 V617F Janus Kinase 2, JAK2 V617F 81270; may apply KRAS, cobas Mutation Test IVD KRAS, KRAS IVD, cobas KRAS, KRAS exon 2, KRAS codons 12 & (88381 may apply) 81301; may apply; MSI by Microsatellite Instability MSI MYD88 L265P Mutation RAS Panel (KRAS exon 3 & 4; NRAS exons 2,3 & 4) 81340; may apply; TCR-beta gene rearrangement TCR-gamma (T-cell) gene rearrangement T cell clonality 81342; may apply; Special Stains Acid Fast Bacteria AFB Special Stains Alcian Blue Special Stains B&B (Brown & Brenn) BBGRAM Special Stains Colloidal Iron Stain Special Stains Congo Red Special Stains Grocott Methenamine Silver GMS Special Stains Masson's Trichrome Trichrome Special Stains Mucin Special Stains Myeloperoxidase (MPO) MPO Special Stains Oil Red O Special Stains Periodic Acid Schiff (PAS) Special Stains Periodic Acid Schiff (PAS) with Diastase Special Stains Perl's Iron Stain Perls Special Stains PTAH Special Stains Reticulin, Gordon & Sweet's Gordon & Sweet's Special Stains Verhoeff Van Gieson (VVG) Special Stains Wright-Giemsa Wright's of 7
TEST MENU
1p36/19q13 - Oligodendroglioma Oligodendroglioma Panel test (1p36/1q25 and 19q13/19p13) 88374x2 1q21+1p21 Myeloma Panel test 88374 7q31 / del 7q 7q31/CEP7 88374 11q22.3 (ATM) CLL/SLL panel test 88374 11q23
More informationTEST MENU
1p36/19q13 - Oligodendroglioma Oligodendroglioma Panel test (1p36/1q25 and 19q13/19p13) 88374x2 1q21+1p21 Myeloma Panel test 88374 7q31 / del 7q 7q31/CEP7 88374 11q22.3 (ATM) CLL/SLL panel test 88374 11q23
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK UCL-Advanced Diagnostics 1st Floor, Rockefeller Building 21 University Street London WC1E 6JJ Contact: David Allen Tel: +44 (0)20 7679 6912
More informationNEW IHC A n t i b o d i e s
NEW IHC Antibodies TABLE OF CONTENTS NEW IHC ANTIBODIES from Cell Marque CITED1 (5H6).... 1 Claudin 7 (5D10F3).... 1 GATA1 (4F5).... 1 Transgelin (2A10C2).... 1 NEW IHC ANTIBODIES using RabMAb Technology
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of ccreditation United Kingdom ccreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK External Quality ssessment Services for Cancer Diagnostics CIC Issue No: 005
More informationantibodies by application
antibodies by application Higher Affinity Higher Sensitivity Higher Specificity A selection of Over 460 Rabbit and Mouse Monoclonal For Use in Clinical and Research Applications Bio SB s RBT & MMab s BSB
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Christie Hospital Manchester M20 4BX Contact: Neil Wrathall Tel: +44 (0) 161 918 7264 Fax: +44 (0) 161 446 8549 E-Mail: neil.wrathall@christie.nhs.uk
More informationHEMATOPATHOLOGY DIAGNOSIS & SUBTYPING. Use of IHC. Use of Polymerase Chain Reaction (PCR) Use of Flow Cytometry
HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING HEMATOPATHOLOGY DIAGNOSIS & SUBTYPING The 2008 WHO classification system for tumors of hematopoietic and lymphoid tissues specifies that various combinations of immunophenotypic
More information2016 Antibodies by Application
2016 by Application Higher Affinity Higher Sensitivity Higher Specificity New Rabbit Monoclonal ALK, EP301 Amyloid A, EP335 B7H3/CD276, RBT B7H3 bcl6, EP278 BRAF V600E, RM8 C4d, EP273 CD5, RED1 CD8, EP334
More informationProtocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012
Protocols for Zytomed Systems antibodies on fully automated IHC staining systems date of issue: September 20, 2012 These protocols were provided by customers. Under no circumstances shall Zytomed Systems
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationIn Situ Hybridization Immunohistochemistry
2013-2014 In Situ Hybridization Immunohistochemistry A History of Delivering Superior Products Genemed Biotechnologies, Inc. was founded in 1987 and is located in the center of the South San Francisco
More informationYour single-source laboratory solution. FISH Probe Library
Your single-source laboratory solution. FISH Probe Library Alphabetical List by Probe with Clinical Indication Probe Clinical Indication 1p36 (TP73)/19q13 (GLTSCR) 1q21 (CKS1B) 5q (CSF1R/RPS14) 7q (MDFIC)
More informationTEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
More informationBreast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
More informationCleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special s Group I for Microorganisms Special s Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram Gridley PAS/light green counterstain Warthin-Starry
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Issue No: 002 Issue date: 05 March 2018 Berkshire and Surrey Pathology Services Department of Histopathology Wexham Park Hospital Slough Berkshire
More informationIHC Panels as an Aid in Diagnostic Decision Making
IHC Antibody Test Selection Using a Panel Approach Steven Westra B.S. Reagent Product Specialist Leica Biosystems IHC Panels as an Aid in Diagnostic Decision Making Diagnostic Use of Tumors Using Algorithms
More informationCovering the continuum with standardof-care, innovative, customized, and clinical research options
Pharma Services Full Service Testing Menu Anatomic Pathology Genomics MultiOmyx Flow Cytometry CDx & IVD Cytogenetics FISH Data Comprehensive testing from one responsive laboratory Covering the continuum
More informationCleveland Clinic Laboratories
Cleveland Clinic Laboratories Anatomic Pathology Special Stains Group I for Microorganisms Special Stains Group I 88312 Fite stain Gomori s methenamine silver (GMS) Gram PAS/light green counterstain Warthin-Starry
More informationThe Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation
The Panel Approach to Diagnostics Lauren Hopson International Product Specialist Cell Marque Corporation Cell Marque Rocklin, California About Cell Marque: IVD primary antibody manufacturer Distributors
More informationmolecular oncology services
Molecular Oncology molecular oncology services ATIENTS.ANSWERS.RESULTS. www.aruplab.com/oncology MARCH 2018 Information in this brochure is current as of March 2018. All content is subject to change. lease
More informationTechnology from Abcam
CD2 (EP222) CD2 is one of the earliest T-cell lineage restricted antigens to appear during T-cell differentiation and only rare CD2+ cells can be found in the bone marrow. Anti-CD2 is a pan-t-cell antigen
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK operating as North East Essex and Suffolk Pathology Service (NEESPS) Cellular Pathology Contact: Lynn Partridge Ipswich Hospital Tel: +44
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service High Street, Feltham, Middlesex, TW13 4UN, UK
21-47 High Street, Feltham, Middlesex, TW13 4UN, UK Cellular Pathology Pathology Department Northampton General Hospital Cliftonville Northampton Northamptonshire NN1 5BD Contact: Mary Pendleton Tel: +44
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Laboratory Contact: Breege Nicholson Queen Elizabeth Hospital Tel: +44 (0) 208 333 3000 ext. 8478 Stadium Road E-Mail:
More informationThe role of immunohistochemistry in surgical pathology of the uterine corpus and cervix
The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix Prof. Ben Davidson, MD PhD Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK 05/09/2018 Cellular Pathology Level 2 Esher Wing Galsworthy Road Kingston upon Thames KT2 7QB Contact: Dr Sussan Gharaie Tel: +44 (0)208 934
More informationADVANCED STAINING PRODUCT CATALOG. In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents
2017 ADVANCED STAINING PRODUCT CATALOG In Situ Hybridization Probes Immunohistochemistry Antibodies Detection Systems Ancillary Reagents A History of Delivering Superior Products Genemed a wholly-owned
More informationHEMATOPATHOLOGY SERVICES
HEMATOPATHOLOGY SERVICES Know what your patient s future holds, NOW. Driven by patient care, GoPath Laboratories has set a new standard for hematologic cancer testing. thick, 2 slides per probe minimum
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationPhenoPath. Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA
PhenoPath Diagnoses you can count on B CELL NON-HODGKIN LYMPHOMA C urrent diagnosis of B cell non-hodgkin lymphoma (B-NHL) is based on the 2008 WHO Classification of Tumours of Haematopoietic and Lymphoid
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationReady-to-use, CE-IVD antibodies for pathology
A-1-Antichymotrypsin A-1-Antitrypsin Abcc3 Aberrant Endothelial 4A11 Cell ACTH BSB-25; AH26 Actin 1A4 Actin, Muscle Specific HHF35 Actin, Smooth Muscle BSB-15 (ASM/H12) Adenovirus 20/11 and 2/6; A62020069A
More informationThe impact of proficiency testing on lab immunoassays
The impact of proficiency testing on lab immunoassays Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark Nordic Immunohistochemical Quality
More informationCost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
More informationCYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING
INTRODUCTION The Cytogenetics Laboratory offers a comprehensive array of chromosome investigations for cancers, constitutional abnormalities, and prenatal and postnatal diagnosis. Analyses are performed
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of Accreditation 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Eye Pathology 1 st Floor, Cayton Street Building UCL Institute of Ophthalmology 11-43 Bath Street
More informationCURRENT AND EMERGING CANCER DIAGNOSTIC TESTS Emerging Assays, and Companies Developing New Technologies and Products.
CURRENT AND EMERGING CANCER DIAGNOSTIC TESTS Emerging Assays, and Companies Developing New Technologies and Products Table of Contents Major Current And Emerging Cancer Diagnostic Tests 1. Introduction
More informationImmunohistochemistry. Potential and challenges To be or not to be
Immunohistochemistry Potential and challenges To be or not to be Søren Nielsen Scheme Manager NordiQC Aalborg University Hospital, Denmark Vårmöte 19.05.2016 Karlstad Overview IHC project coordinator at
More informationHematology Diagnostic Services
Cleveland Clinic Laboratories Hematology Diagnostic Services Trust in us for everything you need in a reference lab. Our Mission The Pathology and Laboratory Medicine Institute contributes to excellent
More informationCharles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources
Charles Halsey, DVM, PhD, DACVP Pfizer, Inc. IHC Resources 1 IHC Identification Targets Specimens Controls 2 Tissue controls Trouble Spots 3 The Key to Description IHC Description 4 Intermediate Filaments
More information5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful
www.ascp.org/ascp2014 5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful Kathryn Rizzo, DO, PhD VIRGINIA COMMONWEALTH UNIVERSITY Department of Pathology School of Medicine
More informationSeptember 04, 2008
27027 Tourney Road Valencia, CA 91355 800 421 7110 www.specialtylabs.com Test Updates September 04, 2008 Dear Valued Client: As you may be aware, in recent years there has been a tremendous challenge in
More informationIIImmunohistochemistry (IHC) Outreach Services
IIImmunohistochemistry (IHC) Outreach Services Note type of fixative used if not neutral buffered formalin. Note type of tissue/specimen Unless specified otherwise, positive and negative controls react
More informationDifferential diagnosis of HCC
Hepatocellular Carcinoma Quest for an Ideal Immunohistochemical Panel Sanjay Kakar, MD UCSF Differential diagnosis of HCC Hepatocellular lesions Adenoma, FNH, HG dysplasia Adenocarcinoma CholangioCA, metastasis
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Cellular Pathology Contact: Dr Nicola Chaston East Kent Hospitals University Tel: +44 (0)1233 616183 NHS Foundation Trust Fax: +44 (0) 01233
More informationImmunohistochemical classification of haematolymphoid tumours. Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital
Immunohistochemical classification of haematolymphoid tumours Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital Malignant lymphoproliferative diseases What are they? Haematolymphoid
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK North Tyneside General Hospital Rake Lane North Shields Tyne & Wear NE29 8NH Contact: Ian Taylor Tel:
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Laboratory locations: Department of Histopathology Royal United Hospitals NHS Foundation Trust Combe Park Bath BA1 3NG Contact: Lesley Shipway
More informationC.L. Davis Foundation Descriptive Veterinary Pathology Course
C.L. Davis Foundation 2015 Descriptive Veterinary Pathology Course IHC Resources IHC Identification Targets Antibodies Antibodies 1 Antibodies Specimens Antigen Retrieval Unmasks antigen epitopes Methods
More informationHSL-Advanced Diagnostics 2018 / 19 Test & Service List
HSL-Advanced Diagnostics 2018 / 19 Test & Service List 2018/19 TEST & SERVICE LIST Haematoxylin & Eosin H&E H&E per slide Routine Immunohistochemistry Immunohistochemical demonstration of an antigen in
More informationDifferential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital
Differential diagnosis of hematolymphoid tumors composed of medium-sized cells Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital Lymphoma classification Lymphoma diagnosis starts with morphologic
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Forth Valley Royal Hospital Stirling Road Larbert FK5 4WR Contact: Suzanne Ferra Tel: 01324 566643 Tel: +44
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK The Princess Alexandra Hospital NHS Trust The Michael Letcher Department of Cellular Pathology The Princess Alexandra Hospital NHS Trust Hamstel
More informationTEST MENU BY SPECIALTY
1 TEST MENU BY SPECIALTY Breast Pathology Surgical excisions, needle core biopsies, and plastic surgery accepted from all sites Assessment of margins Axillary lymph node dissections Sentinel lymph nodes
More informationTumor Markers & Cytopathology
Tumor Markers & Cytopathology Objectives: After learning, student should be able to 1. Describe the basic concepts of tumor markers and Asst. Prof. Prasit Suwannalert, Ph.D. (Email: prasit.suw@mahidol.ac.th)
More informationMolecular Diagnosis. Nucleic acid based testing in Oncology
Molecular Diagnosis Nucleic acid based testing in Oncology Objectives Describe uses of NAT in Oncology Diagnosis, Prediction, monitoring. Genetics Screening, presymptomatic testing, diagnostic testing,
More informationCase year old male with abdominal lymphadenopathy Treated with 8 cycles of R-CHOP One year later B-symptoms and progressive disease
Codirectors Tsieh Sun, M.D., FASCP Francisco Vega, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Houston Texas There is no conflict of interest involved in the content and presentation
More informationClassification! Immunohistochemical classification of haematolymphoid tumours. Malignant lymphoproliferative diseases
Immunohistochemical classification of haematolymphoid tumours Haematolymphoid Neoplasias: Leukaemia vs Lymphoma C L O N A L M A L I G N A N C I E S Stephen Hamilton-Dutoit Institute of Pathology Aarhus
More informationNucleic Acid Testing - Oncology. Molecular Diagnosis. Gain/Loss of Nucleic Acid. Objectives. MYCN and Neuroblastoma. Molecular Diagnosis
Nucleic Acid Testing - Oncology Molecular Diagnosis Nucleic acid based testing in Oncology Gross alterations in DNA content of tumors (ploidy) Gain/Loss of nucleic acids Markers of Clonality Oncogene/Tumor
More informationOutline. Chromosomal analysis FISH. Chromosomal abnormalities in cancer. Clinical application of cytogenetics. Procedure Nomenclature
Outline Chromosomal analysis Procedure Nomenclature FISH Procedure Probes Multicolor-FISH CGH Chromosomal abnormalities in cancer CML, MPD, MDS, AML, ALL, CLL, myeloma, lymphoma Clinical application of
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Contact: Karen Wignall Royal Preston Hospital Tel: +44 (0) 1772 523108 Sharoe Green Lane E-Mail: karen.wignall@lthtr.nhs.uk
More informationImmunopathology of Lymphoma
Immunopathology of Lymphoma Noraidah Masir MBBCh, M.Med (Pathology), D.Phil. Department of Pathology Faculty of Medicine Universiti Kebangsaan Malaysia Lymphoma classification has been challenging to pathologists.
More informationOncology Cytogenetics Diagnostic Service - User Guide 2014
Oncology Cytogenetics Diagnostic Service - User Guide 2014 Contact details Address: Cytogenetics Department 5 th Floor Tower Wing Guy s Hospital Great Maze Pond London SE1 9RT General enquiries 0207 188
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles Multimethod Analysis of 25+ Hematologic Diseases and Solid Tumors Anatomic Pathology FISH Molecular The next generation of diagnostic, prognostic, and therapeutic assessment NeoTYPE
More informationMethods used to diagnose lymphomas
Institut für Pathologie Institut für Pathologie Methods used to diagnose lymphomas Prof. Dr.Med. Leticia Quintanilla-Fend Molecular techniques NGS histology Cytology AS-PCR Sanger seq. MYC Immunohistochemistry
More informationMPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
More informationApplications of IHC. Determination of the primary site in metastatic tumors of unknown origin
Applications of IHC Determination of the primary site in metastatic tumors of unknown origin Classification of tumors that appear 'undifferentiated' by standard light microscopy Precise classification
More informationCutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
More informationBlastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
More informationDOUBLE STAINS. Toll-Free: Direct:
DOUBLE STAINS CD61 + CD71 DAB Brown: CD61 Alk. Phos. Red: CD71 Bone Marrow DAB Brown: Megakaryocytes Alk. Phos. Red: Erythroid Precursors 400x CD61 (2f2) 0.1 ml concentrate............. 161M-14 0.5 ml
More informationTumor Markers: Granular Analysis of the US Market Supplier Shares and Forecasts for 40 Cancer Diagnostic Tests. List of Tables
Tumor Markers: Granular Analysis of the US Market Supplier Shares and Forecasts for 40 Cancer Diagnostic Tests List of Tables Tumor Marker Classification ACTH Tests AFP Tests Beta-2 Microglobulin Tests
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Paediatric Histopathology Western Bank Sheffield S10 2TH United Kingdom Contact: Tel: +44 (0) 1142 717240 Fax: +44 (0) 1142 706121 E-Mail:
More informationYour single-source laboratory solution. Antibody Library
Your single-source laboratory solution. Antibody Library A-ACT Alpha-1 antichymotrypsin; histiocytes; pancreatic pseudopapillary tumor A-AT Alpha-1-antitrypsin; inherited AAT deficiency ACTH Adrenocorticotropic
More informationBasic Immunology. Lecture 26 th. Immunity against tumors
Basic Immunology Lecture 26 th Immunity against tumors Neoplastic transformations are genetic alterations. Expression of cell surface antigens both self and non-self - seen by immune system. Ehrlich positive
More informationHematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018
Hematolymphoid lesions of the skin Part II Myeloid neoplastic proliferations Houston Society of Clinical Pathologists Symposium April 14, 2018 Carlos A. Torres-Cabala, MD Associate Professor Chief, Dermatopathology
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Use of Immunophenotyping/ Genetic Testing in Differential Diagnosis of Mature B-Cell
More informationGENETIC MARKERS IN LYMPHOMA a practical overview. P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute
GENETIC MARKERS IN LYMPHOMA a practical overview P. Heimann Dpt of Medical Genetics Erasme Hospital - Bordet Institute B and T cell monoclonalities Rearrangement of immunoglobin and TCR genes may help
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationMolecular Hematopathology
Molecular Hematopathology Charles E. Hill, MD, PhD Emory University School of Medicine April 2013 The Association for Molecular Pathology Education. Innovation and Improved Patient Care. Advocacy. www.amp.org
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Blizard Institute Core Pathology Pathology and Pharmacy Building Second Floor 80 Newark Street London E1 2ES Contact: Pauline Levey Tel: +44
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Department of Cellular Pathology Dorset County Hospital Williams Avenue Dorchester DT1 2JY Contact: Sharon Wood Tel: +44 (0)1305 254326 E-Mail:
More informationFOLLICULARITY in LYMPHOMA
FOLLICULARITY in LYMPHOMA Reactive Follicular Hyperplasia Follicular Hyperplasia irregular follicles Follicular Hyperplasia dark and light zones Light Zone Dark Zone Follicular hyperplasia MIB1 Follicular
More informationSchedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Calderdale and Huddersfield NHS Foundation Trust Calderdale Royal Hospital Salterhebble Halifax HX3 0PW United Kingdom Contact: Dr Richard
More informationTUMOR M ARKERS MARKERS
TUMOR MARKERS M.Shekarabi IUMS Definition Many cancers are associated with the abnormal production of some molecules l which h can be measured in plasma. These molecules are known as tumor markers. A good
More information7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour
7 Omar Abu Reesh Dr. Ahmad Mansour Dr. Ahmad Mansour -Leukemia: neoplastic leukocytes circulating in the peripheral bloodstream. -Lymphoma: a neoplastic process in the lymph nodes, spleen or other lymphatic
More informationIMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining)
Stain Clear Cell Papillary IMMUNOPROFILES OF THE MAJOR RENAL NEOPLASMS (%staining) Chromophobe Collecting Duct Carcinom a Sarcomatoid Xp11 Translocat ion Dr Jon Oxley See also www.jonoxley.com Page 1 MTSCC
More informationSingle and Multiplex Immunohistochemistry
Single and Multiplex Immunohistochemistry Steve Westra, BS Reagent Product Specialist Leica Biosystems IHC Theory Polyclonal vs Monoclonal Polyclonal reagents Detect a multitude of epitopes Batch to batch
More informationMolecular Diagnostics in the Workup of Lymphomas for the General Pathologist. Outline. Role of Molecular Testing in Lymphoma Diagnosis
Molecular Diagnostics in the Workup of Lymphomas for the General Pathologist L. Jeffrey Medeiros, M.D. M.D. Anderson Cancer Center Outline Gene rearrangement studies / Clonality Translocations / mutations
More informationBone Marrow Processing Overview Document Reference: LP-SI-HMDS_BM Processing Overview
EDITION NUMBER: 1 ACTIVE DATE: 27 th August 2013 REPLACES: - LOCATION OF COPIES: AUTHOR: Date: APPROVED BY: Designation Date: 1) Electronically through Q-Pulse 2) Printed out copy in HODS reception Ulrika
More informationSchedule of Accreditation - draft issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
- draft 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Bournemouth & Christchurch Hospitals NHS Foundation Cellular Pathology Department Royal Bournemouth Hospital Castle Lane East
More informationCorrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run
Corrigenda WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run In addition to corrections of minor typographical errors, corrections
More informationCLL Complete SM Report
Reported: 02/01/2012 Σ CGI ID No:5 Client:r Client Address: CLINICAL DATA: Lymphoma No CBC results provided. CLL Complete SM Report FINAL DIAGNOSIS: CD19+ B cell lymphoma, ZAP-70 + (44%), with borderline
More informationReview and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors
Review and Updates of Immunohistochemistry in Selected Salivary Gland and Head and Neck Tumors. Monophasic tumors : myoepithelioma, acinic cell carcinoma, and salivary duct carcinoma. Biphasic tumors includes
More informationThe spectrum of flow cytometry of the bone marrow
The spectrum of flow cytometry of the bone marrow Anna Porwit Lund University Faculty of Medicine Dept. of Clinical Sciences Div. Oncology and Pathology anna.porwit@med.lu.se Disclosure of speaker s interests
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?!
Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?! Judith A. Ferry Massachusetts General Hospital Disclosure of Relevant Financial Relationships USCAP requires that all
More information